Medication info
Linagliptin/Metformin Extended-Release Tablets 2.5/1000 mg (Linagliptin (Micronized), Metformin Hydrochloride)

Linagliptin/Metformin Extended-Release Tablets 2.5/1000 mg (Linagliptin (Micronized), Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Dongkook Pharmaceutical Co., Ltd.
Appearance
Oval-shaped extended-release tablet with one side inscribed with LK2, white to almost white.
Packaging
PTP - 28 tablets/box [7 tablets/PTP x 4], bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202400608 · Approved 2024.03.22 · Insurance code 653405620

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dosage of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken with food once daily, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate, if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dosage of this drug is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before and periodically during treatment with this drug. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this drug may be used by adjusting the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Dongkook Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with meal and exercise therapy to assist patients with type 2 diabetes in controlling their blood sugar levels by taking Linagliptin and Metformin together. Through this, it effectively manages blood sugar, aiding in the treatment of diabetes.

How to take

Adult dose

In antidiabetic therapy, the dosage of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken with food once daily, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate, if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dosage of this drug is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before and periodically during treatment with this drug. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this drug may be used by adjusting the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication can cause a rare side effect known as severe lactic acidosis; therefore, if any symptoms occur, an immediate visit to a hospital is necessary. Patients with allergies to any component contained in this medication or those with specific conditions like type 1 diabetes, lactic acidosis, or diabetic ketoacidosis should not use it. It is contraindicated for patients with severely impaired kidney function or those in a condition where acute changes in kidney function are expected. Patients with severely compromised heart function, severe lung disease, or liver dysfunction should also refrain from using this medication for safety reasons. Patients with acute or chronic alcohol intoxication, very poor nutritional status, or weakness should also avoid this medication. Due to the risk of hypoglycemia, especially when used in conjunction with other antidiabetic agents, periodic blood sugar checks and dosage adjustments may be necessary. To reduce the risk of lactic acidosis, it is advised to temporarily discontinue this medication during situations affecting kidney function, such as dehydration, severe infections, prior or post-surgery, and prior or post-use of radiologic contrast agents. This medication is primarily excreted through the kidneys; hence, regular kidney function tests should be conducted before and during treatment, and elderly patients should be monitored carefully for kidney function. There may be occurrences of acute pancreatitis or skin blistering diseases; thus, if persistent severe abdominal pain or skin abnormality symptoms develop, consult a doctor immediately. Long-term use may lead to vitamin B12 deficiency, so if anemia or neurological symptoms appear, vitamin B12 levels should be assessed. The tablets must not be chewed, crushed, or divided, but swallowed whole, and it is normal for the tablet shell to be excreted in the stool. When using in conjunction with other medications, interaction possibilities exist; inform your physician or pharmacist about any current medications. It is advisable not to use this medication during pregnancy or breastfeeding, and if planning to conceive, appropriate treatment should be discussed with a doctor. Safety and efficacy concerning children have not been established; therefore, its use is not recommended. In case of overdose, serious side effects like lactic acidosis can occur; seek appropriate medical treatment immediately.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • nasopharyngitis
  • hypersensitivity reactions
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemia
  • taste disturbance
Show 127 more
  • cough
  • loss of appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcers
  • abnormal liver function tests
  • hepatitis
  • itching
  • erythema
  • rash
  • similar to pemphigus
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastases
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus damage
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid enlargement
  • anemia
  • nausea
  • gastroesophageal reflux disease
  • gastritis
  • viral upper respiratory infection
  • upper respiratory infection
  • periodontitis
  • dizziness
  • chest discomfort
  • weakness
  • nosebleed
  • oropharyngeal pain
  • voice disturbance
  • epistaxis
  • runny nose
  • osteoarthritis
  • limb pain
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • male pattern baldness
  • hyperhidrosis
  • dermatitis
  • anxiety
  • confused state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

Store the medication in a tightly closed container to protect it from air and moisture, and keep it at temperatures between 1°C and 30°C. This way, the effectiveness of the medication can be maintained for a longer period.

Appearance and packaging

Appearance

Oval-shaped extended-release tablet with one side inscribed with LK2, white to almost white.

Package unit

PTP - 28 tablets/box [7 tablets/PTP x 4], bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.